Adénofibrome du sein: aspects clinique et thérapeutique au centre hospitalier universitaire Gabriel Touré / Clinical and therapeutic aspects of breast fibroadenoma at the Gabriel Toure University Hospital

L''Adénofibrome est l'affection la plus fréquente des pathologies bénignes du sein. L'objectif était d'identifier les aspects clinique et thérapeutique de l'adénofibrome dans le service de gynécologie obstétrique et chirurgie générale du CHU Gabriel TOURE. Patientes et Méthodes : L'étude était descriptive avec récolte rétrospective des données du 1er juillet 2018 au 31 juillet 2021. Ont été inclus, les dossiers de patientes prises en charge pour adénofibrome selon les principes éthiques garantissant l'anonymat et la confidentialité des données. Résultats : Nous avons recensé 701 cas de pathologie mammaire parmi lesquelles nous avons retenu au total 112 cas d'adénofibrome durant la période d'étude soit 15,9%. Nous avons enregistré 682 cas de tumeur mammaire, l'adénofibrome a représenté 16,42 %. Ainsi parmi toutes les 154 tumeurs bénignes du sein, l'adénofibrome (112 cas) a représenté 72,7%. L'âge moyen était de 27 ans avec un écart type de 14,8 ans (13 ans et 62 ans). La tranche d'âge de 20 à 35 ans était la plus représentée soit 44%. La fréquence de l'adénofibrome diminuait avec l'augmentation de la gestité et de la parité. L'obésité ou le surpoids ont été retrouvés chez 63 des patientes. Le motif principal de consultation était la présence d'une tuméfaction mammaire. L'atteinte unilatérale gauche prédominait dans 46% et la localisation au quadrant supéro- externe représentait 50 %. La résection chirurgicale a représenté la modalité de prise en charge la plus fréquente avec 56,2 % des cas. Conclusion : L'adénofibrome du sein est une affection bénigne assez fréquente. Son diagnostic oblige à une surveillance. Le traitement chirurgical doit être discuté selon l'âge, la taille et la présence de facteurs de risque de malignité

Fibroadenomas are the most common benign breast disorders. The aim of this study was to identify the clinical and therapeutic aspects of fibroadenoma in the obstetric gynecology department and General Surgery of Teaching hospital Gabriel TOURE in Bamako Mali. Patients and Methods: The study was descriptive with retrospective data collection from July 1, 2018 to July 31, 2021. The records of patients treated for fibroadenoma were included in accordance with ethical principles guaranteeing anonymity and confidentiality of data. Results: A total of 112 patients were selected for the study period, representing 15. 9% of all breast pathologies. We recorded 642 cases of breast mass, with fibroadenoma accounting for 16.72% of these breast tumors. Among all 154 benign breast tumors, fibroadenoma accounted for 72%. The mean age was 27 years, with a standard deviation of 14.8 years (13 years and 62 years). The 20-35 age group was the most represented, at 44%. The frequency of fibroadenoma decreased with increasing gestational age and parity. Over 60% of patients were overweight. The main reason for consultation was the presence of breast swelling. Unilateral left breast swelling was predominant in 46% of cases, and location in the upper-outer quadrant accounted for 50%. Surgical excision was the most frequent management modality, accounting for 56,2% of cases. Conclusion: fibroadenoma of the breast are a fairly common benign condition. Diagnosis requires surveillance. Surgical treatment should be discussed according to age, size and the presence of risk factors for malignancy.

Benign core biopsy of probably benign breast lesions 2 cm or larger: correlation with excisional biopsy and long-term follow-up

PURPOSE: To evaluate the accuracy of benign core biopsy of probably benign breast lesions (category 3) 2 cm or larger on the basis of excisional biopsy and long-term follow-up. METHODS: We retrospectively reviewed 146 category 3 lesions in 146 patients 2 cm or larger which were diagnosed as benign by ultrasound (US)-guided core biopsy. Patients were initially diagnosed as benign at core needle biopsy and then followed up with excisional biopsy (surgical excision, n=91; US-guided vacuum assisted excision, n=35) or breast ultrasonography (n=20). RESULTS: Of the 126 patients who underwent surgical excision or US-guided vacuum-assisted excision, 114 patients were diagnosed with benign lesions, 10 patients with borderline lesions (benign phyllodes tumor), and two patients with malignant phyllodes tumors. The probabilities of lesions being benign, borderline and malignant were 91.8% (134/146), 6.8% (10/146), and 1.4% (2/146), respectively. Of 13 patients who had growing masses on follow-up ultrasonography, three (23.1%) were non-benign (two benign phyllodes tumors and one malignant phyllodes tumor). CONCLUSION: US-guided core needle biopsy of probably benign breast mass 2 cm or larger was accurate (98.6%) enough to rule out malignancy. But, it was difficult to rule out borderline lesions even when they were diagnosed as benign.

Magnetic Resonance Findings of Breast Diseases / 한국유방암학회지

Contrast-enhanced magnetic resonance imaging (MRI) of the breast is probably the most sensitive method for the detection of the pathology of the breast. It is an emerging technology that may revolutionize the management of women with known or suspected breast cancer. Recently, breast MRI has proven most useful in patients with proven breast cancer for the assessment of a multifocal/multicentric disease, chest wall involvement, chemotherapy response, or tumor recurrence or to identify the primary site in patients with occult breast cancer. False positive findings can pose a significance problem in the interpretation of a breast MRI. MRI examinations should be interpreted with an awareness of the pitfalls, false positive breast lesions, and artifacts that can affect on the image evaluation.